

Supplementary Table 2. Univariable and multivariable analyses of disease-free and overall survival for the prospective real-world cohort (N=1813)

Variable	Groups	Disease-free survival				Overall survival			
		Univariable HR	P	Multivariable HR*	P	Univariable HR	P	Multivariable HR*	P
Age	≤70	-		-		-		-	
	>70	1.58 (1.26-1.98)	<0.001	1.24 (0.90-1.71)	0.182	2.48 (1.77-3.48)	<0.001	1.38 (0.87-2.21)	0.173
Gender	Male	-		-		-		-	
	Female	0.75 (0.60-0.95)	0.015	0.85 (0.65-1.11)	0.227	0.75 (0.55-1.04)	0.086	0.96 (0.65-1.41)	0.823
ECOG status	0	-		-		-		-	
	≥1	1.65 (1.30-2.08)	<0.001	1.42 (1.05-1.93)	0.024	2.93 (2.09-4.12)	<0.001	2.14 (1.40-3.32)	0.001
ASA score	1-2	-		-		-		-	
	≥3	1.45 (1.14-1.84)	0.002	1.06 (0.80-1.42)	0.669	3.01 (2.11-4.30)	<0.001	1.77 (1.15-2.74)	0.010
Primary tumor location	Right colon	-		-		-		-	
	Left colon or rectum	1.00 (0.80-1.25)	0.992	0.94 (0.72-1.23)	0.670	0.90 (0.66-1.24)	0.520	0.89 (0.61-1.31)	0.561
Campus type	Public	-		-		-		-	
	Private	0.61 (0.46-0.80)	<0.001	0.52 (0.36-0.76)	0.001	0.26 (0.16-0.44)	<0.001	0.21 (0.10-0.43)	<0.001
IRSAD	Intermediate-High	-		-		-		-	
	Low	0.88 (0.65-1.18)	0.387	0.85 (0.61-1.19)	0.335	1.07 (0.72-1.58)	0.752	0.88 (0.56-1.37)	0.570
Smoking history	Former or never	-		-		-		-	
	Current	1.14 (0.82-1.58)	0.452	1.23 (0.84-1.80)	0.294	1.37 (0.89-2.13)	0.154	1.57 (0.93-2.64)	0.088
Presentation	Screen-detected	-		-		-		-	
	Other	1.99 (1.35-2.94)	0.001	1.38 (0.90-2.11)	0.140	2.78 (1.46-5.28)	0.002	1.44 (0.72-2.87)	0.300
Diabetes	No	-		-		-		-	
	Yes	1.29 (1.00-1.67)	0.054	1.10 (0.81-1.50)	0.537	1.67 (1.18-2.36)	0.004	1.11 (0.73-1.68)	0.622
Post-operative complications	No	-		-		-		-	
	Yes	1.98 (1.56-2.52)	<0.001	1.65 (1.25-2.17)	<0.001	2.70 (2.10-4.19)	<0.001	1.90 (1.27-2.85)	0.002
Adjuvant chemotherapy									
Stage II	No	-		-		-		-	
	Yes	0.58 (0.34-0.99)	0.045	0.91 (0.47-1.76)	0.783	0.25 (0.09-0.67)	0.006	0.30 (0.07-1.30)	0.108
Stage III	No	-		-		-		-	
	Yes	0.37 (0.26-0.51)	<0.001	0.33 (0.20-0.53)	<0.001	0.19 (0.11-0.31)	<0.001	0.22 (0.11-0.45)	<0.001
Trial participation	No	-		-		-		-	
	Yes	0.67 (0.52-0.88)	0.003	0.81 (0.60-1.11)	0.198	0.52 (0.35-0.77)	0.001	0.69 (0.43-1.10)	0.120

ASA; American Society of Anesthesiologists, ECOG; Eastern Co-operative Oncology Group, IRSAD; Index of Relative Socioeconomic Advantage and Disadvantage

*Only in 1319 patients with complete data for all variables (225 DFS events, 112 OS events)